Patent: 9,850,239
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Summary for Patent: 9,850,239
| Title: | Pyrazolo[3,4-c]pyridine compounds and methods of use |
| Abstract: | Pyrazolo[3,4-c]pyridine compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R.sup.1 and R.sup.2 are as defined herein, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. ##STR00001## |
| Inventor(s): | Do; Steven (San Jose, CA), Hu; Huiyong (San Mateo, CA), Kolesnikov; Aleksandr (San Francisco, CA), Lee; Wendy (San Ramon, CA), Tsui; Vickie Hsiao-Wei (Burlingame, CA), Wang; Xiaojing (Foster City, CA), Wen; Zhaoyang (San Francisco, CA) |
| Assignee: | Genentech, Inc. (South San Francisco, CA) |
| Application Number: | 15/044,231 |
| Patent Claims: | see list of patent claims |
Details for Patent 9,850,239
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | See Plans and Pricing | 2031-08-12 |
| Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | See Plans and Pricing | 2031-08-12 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
